INNATE PHARMA: Investor & Analyst Update, New York, May 16th, 2016
16 Mai 2016 - 2:24PM
Innate Pharma SA (the "Company" - Euronext Paris: FR0010331421 -
IPH), the innate immunity company developing first-in-class
therapeutic antibodies for cancer and inflammatory diseases, will
today hold an Investor & Analyst Update in New York, USA, from
12:00 to 3:00 pm ET (6:00 to 9:00 pm CET) at NY Palace Hotel, 455
Madison Ave, Spellman Room (5th Floor).
During the meeting, Hervé Brailly, Chief
Executive Officer of Innate Pharma, will provide a corporate
strategy update including the Company's approaches towards becoming
an integrated biopharmaceutical company.
Nicolai Wagtmann, Chief Scientific Officer of
Innate Pharma, will discuss Innate's ongoing development programs,
science and R&D strategy in immuno-oncology including:
- An update on the
underlying science and preclinical data supporting the development
of the Company's first-in-class checkpoint antibodies targeting NK
receptors;
- A description of
a new NKp46 bispecific antibody platform;
- The Company's
approach to using novel antibodies for targeting the tumor
microenvironment
For live webcast and replay, please go to:
http://lifesci.rampard.com/20160516/reg.jsp
About Innate Pharma:
Innate Pharma S.A. is a biopharmaceutical
company discovering and developing first-in-class therapeutic
antibodies for the treatment of cancer and inflammatory
diseases.
Innate Pharma specializes in immuno-oncology, a
new therapeutic field that is changing cancer treatment by
enhancing the capability of the body's own immune cells to
recognize and kill cancer cells.
The Company has pioneered the development of
antibodies that block inhibitory checkpoint receptors on NK cells.
Today, Innate Pharma has three first-in-class antibodies in
clinical development in immuno-oncology and a pipeline of
preclinical candidates to novel targets and mechanisms.
Its innovative approach has translated into
alliances with leaders in the biopharmaceutical industry such as
AstraZeneca, Bristol-Myers Squibb, Novo Nordisk A/S and Sanofi.
Based in Marseille, France, Innate Pharma had
122 employees as at March 31, 2016. The company is listed on
Euronext Paris.
Learn more about Innate Pharma at
www.innate-pharma.com.
Practical Information about Innate Pharma
shares:
ISIN
code Ticker code |
FR0010331421 IPH |
Disclaimer:
This press release contains certain
forward-looking statements. Although the company believes its
expectations are based on reasonable assumptions, these
forward-looking statements are subject to numerous risks and
uncertainties, which could cause actual results to differ
materially from those anticipated. For a discussion of risks and
uncertainties which could cause the company's actual results,
financial condition, performance or achievements to differ from
those contained in the forward-looking statements, please refer to
the Risk Factors ("Facteurs de Risque") section of the Document de
Reference prospectus filed with the AMF, which is available on the
AMF website (http://www.amf-france.org) or on Innate Pharma's
website.
This press release and the information contained
herein do not constitute an offer to sell or a solicitation of an
offer to buy or subscribe to shares in Innate Pharma in any
country.
For additional information, please
contact:
Innate Pharma |
Press Contacts |
Laure-Hélène Mercier Director,
Investor Relations |
ATCG
Press (France) Marie Puvieux |
Tel.: +33 (0)4 30 30 30 87 |
Mob: +33
(0)6 10 54 36 72 |
investors@innate-pharma.com |
presse@atcg-partners.com |
|
Consilium Strategic Communications (ROW) |
|
Mary-Jane Elliott / Sue Stuart / Jessica Hodgson / Hendrik
Thys |
|
Tel.: +44 (0)20 3709
5700 |
|
InnatePharma@consilium-comms.com |
Investor & Analyst Update, New York, May 16th, 2016
http://hugin.info/155662/R/2012952/745864.pdf
HUG#2012952
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Innate Pharma (EU:IPH)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024